UncoveRNAi · Deciphering the mechanisms of antiviral RNA interference in mammals
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2019-07-01 → 2021-06-30
- EU contribution
- €212,934
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
Deciphering the mechanisms of antiviral RNA interference in mammals
Introduction, objectives and importance Stem cells play a fundamental role in the maintenance of adult tissue architecture and integrity by providing a pool of differentiated cells through asymmetric division (1). Therefore, they must shield from endogenous threats, such as transposable elements, as well as from exogenous insults, e.g. genotoxic stress or viral infections. Early antiviral responses in mammals rely on the expression of type I and type III interferons (IFN), which act on differentiated cells in an autocrine and paracrine manner to promote the transcription of interferon stimulated genes (ISGs) that encode antiviral effector proteins (2). However, protection conferred by the IFN pathway is severely compromised in embryonic and adult stem cells, which lack key components of the pathway (3). IFN incompetence may ensure that stem cells are protected from the cytostatic properties of IFN, such as antiproliferative and proapoptotic effects. Despite their IFN unresponsiveness, stem cells are largely resistant to viral infection, which can be attributed in part to the steady-state expression of ISGs and other factors restricting infection (4). Nonetheless, immune responses in stem cells remain poorly characterised. In invertebrates and plants, antiviral immunity relies on RNA interference (RNAi), which is initiated by the cleavage of viral double-stranded RNA (dsRNA) by a Dicer protein, generating small interfering RNAs (siRNAs) which guide the degradation of viral RNA (3). Irrespective of infection, RNAi also has a role in regulating cellular gene expression via micro RNAs (miRNAs) produced by Dicer through cleavage of pre-miRNAs. Organisms that use RNAi both as an antiviral response and as a way of regulating mRNA translation with miRNAs have several Dicer genes, the product of which are dedicated to processing either dsRNA or pre-miRNAs (5). In mammals, a single Dicer gene has been described, which encodes a Dicer protein that generates miRNAs but cleaves dsRNA only poorly (6). Whether antiviral RNAi exists in mammalian cells and is relevant to immunity remains highly controversial (3). This project aims at delineating the role and importance of antiviral RNAi in mammals, by answering three mains questions: where does antiviral RNAi happen in vivo, how does it happen, and what is its importance in antiviral immunity compare to IFN activation. Understanding the role and importance of antiviral RNAi in mammals will advance basic knowledge of mammalian immunity, and could also pave the way to innovative antiviral therapies in humans. Conclusions of the action An novel isoform of Dicer, termed antiviral Dicer (aviD) was discovered in the course of this work. This isoform is expressed in mouse and human stem cells within tissues, and protects them against viruses such as Zika virus or severe acute respiratory syndrome coronavirus 2, by implementing canonical antiviral RNAi. References 1. E. Batlle, H. Clevers, Nat. Med. 23, 1124–1134 (2017). 2. X. Tan, L. Sun, J. Chen, Z. J. Chen, Annu. Rev. Microbiol. 72, 447–478 (2018). 3. P. V. Maillard, A. G. Veen, E. Z. Poirier, C. Reis e Sousa, EMBO J. 38 (2019), doi:10.15252/embj.2018100941. 4. X. Wu et al., Cell (2017), doi:10.1016/j.cell.2017.11.018. 5. S.-W. Ding, Nat. Rev. Immunol. 10, 632–644 (2010). 6. E. Ma, I. J. MacRae, J. F. Kirsch, J. A. Doudna, J. Mol. Biol. 380, 237–243 (2008).
Data: CORDIS, © European Union
Project objective
Organisms such as plants, worms or insects rely on RNA interference (RNAi) to mount an antiviral immune response. On the other hand, it is widely believed that the type I interferon (IFN-I) pathway replaced antiviral RNAi as a primary line of defence against viral infections in chordates. However, recent work from multiple teams, including the host laboratory, has described a possible antiviral role for RNAi in cultured mammalian cells and in mice during infection with different RNA viruses. The importance of RNAi as an antiviral mechanism in mammals remains a matter of great controversy, in part due to a dearth of in vivo studies. In particular, the cell type(s) performing RNAi in vivo remains unknown, as is the relative importance of antiviral RNAi compare to the IFN-I response. I propose to decipher the mechanism and importance of antiviral RNAi in mice, by answering three main questions: 1) Where is antiviral RNAi happening? I will identify cell types implicated in antiviral RNAi using reporter viruses and permanent genetic marking of RNAi-competent cells. In parallel with these unbiased approaches, I will study antiviral immune responses in specific cell types likely to rely on antiviral RNAi, such as stem cells. 2) How is antiviral RNAi happening? I hypothesise that antiviral RNAi relies on truncated isoforms of Dicer expressed in specific cell types, and/or production of viral DNA as a means of boosting the RNAi response. I will explore both possibilities in detail. 3) What is the importance of antiviral RNAi? I will specifically ablate antiviral RNAi in cell niches that use this defence mechanism to assess its importance with respect to IFN-I. Overall, my work aims at dissecting antiviral RNAi pathways in mammals and assessing their in vivo significance. This work will provide answers to important questions in the field of antiviral immunity and will potentially open up new areas of research in human health.
Original text from CORDIS.
Participants
- THE FRANCIS CRICK INSTITUTE LIMITED · LondonCoordinatorUnited Kingdom
Links
Data: CORDIS, © European Union
